SG11201407316QA - Compositions and methods for the treatment of hyperglycemia - Google Patents
Compositions and methods for the treatment of hyperglycemiaInfo
- Publication number
- SG11201407316QA SG11201407316QA SG11201407316QA SG11201407316QA SG11201407316QA SG 11201407316Q A SG11201407316Q A SG 11201407316QA SG 11201407316Q A SG11201407316Q A SG 11201407316QA SG 11201407316Q A SG11201407316Q A SG 11201407316QA SG 11201407316Q A SG11201407316Q A SG 11201407316QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- hyperglycemia
- treatment
- compositions
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 November 2013 (14.11.2013) WIPOIPCT (10) International Publication Number WO 2013/167995 A2 (51) International Patent Classification: Not classified (21) International Application Number: (22) International Filing Date: (25) Filing Language: PCT/IB2013/050903 3 February 2013 (03.02.2013) English (26) Publication Language: (30) Priority Data: 181 l/CHE/2012 8 May 2012 (08.05.2012) English IN (84) (72) Inventor; and (71) Applicant : KANDULA, Mahesh [IN/IN]; Door No. 11- 61, Samalkot Mandal, East Godavari Dist, G.Medapadu 533 434, Andhra Pradesh (IN). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) CJ as as i-H cn i-H o CJ o & (54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERGLYCEMIA (57) Abstract: The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof The pharmaceutical compositions comprising an effective amount of com pounds of formula (I), and methods for the treatment of hyperglycemia may be formulated for oral, buccal, rectal, topical, trans - dermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of in sulin resistance, diabetes mellitus, diabetes insipidus, type diabetes, 1 type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hy pertriglyceridemia, cardiovascular complications, and post prandial hyperglycemia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1811CH2012 | 2012-05-08 | ||
PCT/IB2013/050903 WO2013167995A2 (en) | 2012-05-08 | 2013-02-03 | Compositions and methods for the treatment of hyperglycemia |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407316QA true SG11201407316QA (en) | 2014-12-30 |
Family
ID=54193690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407316QA SG11201407316QA (en) | 2012-05-08 | 2013-02-03 | Compositions and methods for the treatment of hyperglycemia |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2016510306A (en) |
CN (1) | CN104812737A (en) |
AU (1) | AU2013257716A1 (en) |
CA (1) | CA2873087A1 (en) |
SG (1) | SG11201407316QA (en) |
WO (1) | WO2013167995A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016198971A1 (en) * | 2015-06-08 | 2016-12-15 | Mohan M Alapati | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3992441A (en) * | 1972-12-26 | 1976-11-16 | Pfizer Inc. | Sulfamylbenzoic acids |
JPS5283951A (en) * | 1976-01-01 | 1977-07-13 | Nippon Shinyaku Co Ltd | Remedy for hyperglycemia and depressant for lipid-biosythesis |
JPS5943946B2 (en) * | 1978-04-28 | 1984-10-25 | 日本新薬株式会社 | N-alkenylmoranoline derivative |
DE3737523A1 (en) * | 1987-11-05 | 1989-05-18 | Bayer Ag | USE OF SUBSTITUTED HYDROXYPIPERIDINES AS ANTIVIRAL AGENTS |
JPH01308229A (en) * | 1988-02-23 | 1989-12-12 | Glaxo Group Ltd | Heterocyclic derivative |
JPH06329671A (en) * | 1993-05-21 | 1994-11-29 | Tsumura & Co | New alkaloid and its use |
CA2128044C (en) * | 1993-08-05 | 2007-02-20 | Klaus-Dieter Bremer | Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor |
WO2004007524A2 (en) * | 2002-07-17 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic oligopeptides |
WO2006102029A2 (en) * | 2005-03-21 | 2006-09-28 | Dov Pharmaceutical, Inc. | Methods and compositions for the treatment of urinary incontinence |
CN101129476B (en) * | 2006-08-21 | 2013-07-24 | 中国医学科学院药物研究所 | Application of mulberry twigs alkaloid valid target in preparing antidiabetics medicament |
EP1903034A1 (en) * | 2006-09-19 | 2008-03-26 | Technische Universität Graz | Iminosugar glycoconjugates |
CA2687715A1 (en) * | 2007-05-09 | 2008-11-20 | Traffick Therapeutics Inc. | Screening assay to identify correctors of protein trafficking defects |
GB0809360D0 (en) * | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
WO2010015816A2 (en) * | 2008-08-06 | 2010-02-11 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
NZ601698A (en) * | 2010-01-08 | 2015-04-24 | Catabasis Pharmaceuticals Inc | Fatty acid fumarate derivatives and their uses |
-
2013
- 2013-02-03 AU AU2013257716A patent/AU2013257716A1/en not_active Abandoned
- 2013-02-03 JP JP2015510897A patent/JP2016510306A/en active Pending
- 2013-02-03 CA CA2873087A patent/CA2873087A1/en not_active Abandoned
- 2013-02-03 WO PCT/IB2013/050903 patent/WO2013167995A2/en active Application Filing
- 2013-02-03 SG SG11201407316QA patent/SG11201407316QA/en unknown
- 2013-02-03 CN CN201380030654.2A patent/CN104812737A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2013167995A2 (en) | 2013-11-14 |
CA2873087A1 (en) | 2013-11-14 |
JP2016510306A (en) | 2016-04-07 |
AU2013257716A1 (en) | 2014-11-27 |
WO2013167995A3 (en) | 2016-09-01 |
CN104812737A (en) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201407411SA (en) | Compositions and methods for the treatment of metabolic syndrome | |
SG11201407326XA (en) | Compositions and methods for treatment of mucositis | |
SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201408094YA (en) | Neprilysin inhibitors | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201407319YA (en) | Compositions and methods for treatment of inflammatory bowel disease | |
SG11201407533SA (en) | Antiviral compounds | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
SG11201407662WA (en) | Process for the preparation of treprostinil and derivatives thereof | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201408261UA (en) | Syringe | |
SG11201407596TA (en) | Conjugation reagents | |
SG11201407303SA (en) | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders | |
SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
SG11201408739VA (en) | Inhibitors of hepatitis c virus | |
SG11201806485RA (en) | Pyrrolobenzodiazepine conjugates | |
SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
SG11201408198QA (en) | Jumper tube locking assembly and method | |
SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201407323WA (en) | Compositions and methods for the treatment of local pain |